Reform des chirurgischen Tertials im Praktischen Jahr an der Ludwig-Maximilians-Universität München

Autor: D. Nörenberg, S. Alig, K. Schinke, Steffen Tiedt, D. Noerenberg, K. Singer, G. Wypior, S. Kruger, S.-K. Kirchner, P. Guder, V. C. Ruf, H. J. Bauer, Matthias Angstwurm, R. Kunisch, L. Weckbach

Publikováno v: Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie. 141:310-314

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86639bbceb8b67415a3aa592f26cc746
https://doi.org/10.1055/s-0034-1396254

Molecular imaging in cardiovascular diseases

Autor: A. J. Wiethoff, Gerd Diederichs, Marcus R. Makowski, Thula Walter, Christian Jansen, D. Noerenberg, M. Kasner, Peter Hoppe, Andreas Schuster, René M. Botnar, Hans U. Ebersberger, Gesine Knobloch, Bernd Hamm

Publikováno v: RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 187(2)

Cardiovascular diseases remain the leading cause of morbidity and mortality in industrialized and developing countries. In clinical practice, the in-vivo identification of atherosclerotic lesions, which can lead to complications such as heart attack

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::660bc3249d021a5381df853fab078697
https://pubmed.ncbi.nlm.nih.gov/25585260

Beyond the code: the role of histone methylation in cancer resistance and therapy.

Autor: Noerenberg D; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany., Damm F; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany. frederik.damm@charite.de.; German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Partner Site, Berlin, Germany. frederik.damm@charite.de.

Publikováno v: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Jun 12; Vol. 9 (1), pp. 161. Date of Electronic Publication: 2024 Jun 12.

Transcriptional reprogramming by mutated IRF4 in lymphoma.

Autor: Schleussner N; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Cauchy P; Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.; University Medical Center Freiburg, 79106, Freiburg, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany., Franke V; Bioinformatics and Omics Data Science Platform, Berlin Institute for Medical Systems Biology, Max-Delbrück-Center, Berlin, Germany., Giefing M; Institute of Human Genetics, Polish Academy of Sciences, Poznan, 60-479, Poland.; Institute of Human Genetics, Christian-Albrechts-University Kiel, 24105, Kiel, Germany., Fornes O; Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, V5Z 4H4, Canada., Vankadari N; Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3000, Australia., Assi SA; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Costanza M; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Weniger MA; Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, 45122, Essen, Germany., Akalin A; Bioinformatics and Omics Data Science Platform, Berlin Institute for Medical Systems Biology, Max-Delbrück-Center, Berlin, Germany., Anagnostopoulos I; Institute of Pathology, Universität Würzburg and Comprehensive Cancer Centre Mainfranken (CCCMF), Würzburg, Germany., Bukur T; TRON gGmbH - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany., Casarotto MG; Research School of Biology, The Australian National University, Canberra, ACT, Australia., Damm F; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany., Daumke O; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Structural Biology, 13125, Berlin, Germany., Edginton-White B; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Gebhardt JCM; Department of Physics, Institute of Biophysics, Ulm University, Ulm, Germany., Grau M; Department of Physics, University of Marburg, 35052, Marburg, Germany.; Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Grunwald S; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Structural Biology, 13125, Berlin, Germany., Hansmann ML; Frankfurt Institute of Advanced Studies, Frankfurt am Main, Germany.; Institute for Pharmacology and Toxicology, Goethe University, Frankfurt am Main, Germany., Hartmann S; Dr. Senckenberg Institute of Pathology, Goethe University Frankfurt, Frankfurt am Main, Germany., Huber L; Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany., Kärgel E; Signal Transduction in Tumor Cells, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Lusatis S; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Noerenberg D; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany., Obier N; Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Pannicke U; Institute for Transfusion Medicine, University of Ulm, Ulm, Germany., Fischer A; Institute of Human Genetics, Ulm University and Ulm University Medical Center, 89081, Ulm, Germany., Reisser A; Department of Physics, Institute of Biophysics, Ulm University, Ulm, Germany., Rosenwald A; Institute of Pathology, Universität Würzburg and Comprehensive Cancer Centre Mainfranken (CCCMF), Würzburg, Germany., Schwarz K; Institute for Transfusion Medicine, University of Ulm, Ulm, Germany.; Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg-Hessen, Ulm, Germany., Sundararaj S; Research School of Biology, The Australian National University, Canberra, ACT, Australia., Weilemann A; Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Winkler W; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Xu W; Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Lenz G; Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Rajewsky K; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Immune Regulation and Cancer, 13125, Berlin, Germany., Wasserman WW; Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, V5Z 4H4, Canada., Cockerill PN; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Scheidereit C; Signal Transduction in Tumor Cells, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Siebert R; Institute of Human Genetics, Christian-Albrechts-University Kiel, 24105, Kiel, Germany.; Institute of Human Genetics, Ulm University and Ulm University Medical Center, 89081, Ulm, Germany., Küppers R; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.; Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, 45122, Essen, Germany., Grosschedl R; Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany., Janz M; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Bonifer C; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Mathas S; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany. stephan.mathas@charite.de.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany. stephan.mathas@charite.de.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany. stephan.mathas@charite.de.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany. stephan.mathas@charite.de.

Publikováno v: Nature communications [Nat Commun] 2023 Nov 07; Vol. 14 (1), pp. 6947. Date of Electronic Publication: 2023 Nov 07.

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.

Autor: Liebers N; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany., Duell J; Department of Internal Medicine II, Würzburg University Hospital, University of Würzburg, Würzburg, Germany., Fitzgerald D; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; European Molecular Biology Laboratory, Heidelberg, Germany., Kerkhoff A; Department of Medicine A, University Hospital Münster, Münster, Germany., Noerenberg D; Department of Hematology, Oncology and Tumor Immunology (Campus Virchow-Klinikum), Charité University Medicine, Berlin, Germany., Kaebisch E; Department of Hematology, Oncology and Tumor Immunology (Campus Virchow-Klinikum), Charité University Medicine, Berlin, Germany., Acker F; Department of Medicine 2, Hematology and Oncology, University Hospital Frankfurt, Frankfurt, Germany., Fuhrmann S; Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany., Leng C; Department of Hematology, Oncology, and Tumor Immunology (Campus Benjamin Franklin), Charité University Medicine, Berlin, Germany., Welslau M; MVZ am Klinikum Aschaffenburg, Onkologie und Hämatologie, Aschaffenburg, Germany., Chemnitz J; Gemeinschaftsklinikum Mittelrhein GmbH, Koblenz, Germany., Middeke JM; University Hospital Dresden, Dresden, Germany., Weber T; Department of Medicine IV, Hematology and Oncology, University of Halle, Halle, Germany., Holtick U; Department I of Internal Medicine, Medical Faculty and University Hospital, Cologne, University of Cologne, Cologne, Germany., Trappe R; Department of Hematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus Bremen, Bremen, Germany., Pfannes R; Department of Medicine I, Städtisches Klinikum Dessau, Dessau, Germany., Liersch R; Praxis Medical Center, Gemeinschaftspraxis für Hämatologie und Onkologie Münster, Münster, Germany., Spoer C; MVZ am EVK Düsseldorf, Internistische Onkologie und Hämatologie, Düsseldorf, Germany., Fuxius S; Onkologische Schwerpunktpraxis Heidelberg, Heidelberg, Germany., Gebauer N; Department of Haematology and Oncology, University Hospital of Schleswig-Holstein, Campus Lübeck, Germany., Caillé L; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Geer T; Diakonie Klinikum Schwäbisch-Hall, Innere Medizin III, Schwäbisch Hall, Germany., Koenecke C; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Keller U; Department of Hematology, Oncology, and Tumor Immunology (Campus Benjamin Franklin), Charité University Medicine, Berlin, Germany., Claus R; Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany., Mougiakakos D; Department of Internal Medicine 5, Hematology and Clinical Oncology, Friedrich-Alexander University (FAU) of Erlangen-Nuremberg, Erlangen, Germany., Mayer S; Department of Internal Medicine III, University Hospital of Regensburg, Regensburg, Germany., Huettmann A; Department of Hematology, University Hospital of Essen, Essen, Germany., Pott C; Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Germany., Trummer A; Department of Hematology and Oncology, Klinikum Braunschweig, Braunschweig, Germany., Wulf G; Clinic for Hematology and Medical Oncology, University Medicine Göttingen, Germany; and., Brunnberg U; Department of Medicine 2, Hematology and Oncology, University Hospital Frankfurt, Frankfurt, Germany., Bullinger L; Department of Hematology, Oncology and Tumor Immunology (Campus Virchow-Klinikum), Charité University Medicine, Berlin, Germany., Hess G; Department of Hematology, Oncology and Pneumology, Johannes Gutenberg-University, Mainz, Germany., Mueller-Tidow C; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany., Glass B; Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany., Lenz G; Department of Medicine A, University Hospital Münster, Münster, Germany., Dreger P; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Dietrich S; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.; European Molecular Biology Laboratory, Heidelberg, Germany.

Publikováno v: Blood advances [Blood Adv] 2021 Jul 13; Vol. 5 (13), pp. 2707-2716.